b
r
c
bdarabinouridin
arau
uridin
analogu
anticanc
agent
arac
synthes
evalu
antivir
activ
cytotox
addit
seri
arau
monophosph
prodrug
form
triester
phosphoramid
protid
also
synthes
test
rang
virus
leukaemia
solid
tumour
cell
line
unfortun
neither
parent
compound
arau
protid
show
antivir
activ
potent
inhibitori
activ
cancer
cell
line
therefor
metabol
arau
phosphoramid
releas
arau
monophosph
investig
result
show
carboxypeptidas
hog
liver
esteras
crude
cem
tumor
cell
extract
hydrolys
ester
motif
phosphoramid
subsequ
loss
aryl
group
molecular
model
studi
suggest
arau
lalanin
aminoacyl
phosphat
deriv
might
good
substrat
phosphoramidas
enzym
find
agreement
observ
disappear
intact
prodrug
concomit
appear
correspond
phosphoramid
intermedi
deriv
cem
cell
extract
without
measur
format
arau
monophosph
find
may
explain
poor
antiviralcytostat
potenti
prodrug
cytarabin
arac
fig
anticanc
drug
use
treatment
acut
myeloid
leukaemia
lymphoma
limit
activ
solid
tumor
prodrug
requir
convers
activ
triphosph
deriv
cellular
kinas
order
exert
cytotox
effect
upon
incorpor
aractp
grow
dna
chain
dna
polymeras
chain
elong
process
termin
work
uridin
deriv
arac
arau
fig
synthes
investig
anticanc
activ
particular
activ
versu
sever
leukaemia
cell
line
examin
arau
fact
metabolit
arac
vivo
result
action
cytidin
deaminas
gener
regard
deactiv
mechan
arac
parallel
mechan
action
arac
arau
would
like
phosphoryl
triphosph
deriv
order
exert
therapeut
effect
may
ineffici
phosphoryl
nucleosid
analogu
particular
first
step
believ
ratelimit
process
mani
antivir
anticanc
nucleosid
thu
seri
arau
triester
phosphoramid
protid
would
bypass
first
phosphoryl
step
synthes
evalu
antivir
activ
cytotox
potenti
select
leukaemia
cell
line
triester
phosphoramid
approach
pronucleotid
approach
deliv
nucleosid
analogu
carbohydr
monophosph
cell
approach
charg
phosphat
motif
fulli
mask
allow
good
passiv
membran
diffus
upon
enter
cell
mask
group
hydrolyz
releas
nucleosid
analoguecarbohydr
monophosph
case
nucleosid
may
phosphoryl
diand
triphosph
deriv
metabol
phosphoramid
proce
four
step
two
spontan
two
involv
enzym
work
twoenzymat
metabol
step
arau
phosphoramid
investig
first
enzymat
step
hydrolysi
ester
motif
phosphoramid
case
studi
use
carboxypeptidas
shown
abl
perform
hydrolysi
ester
moieti
present
phosphoramid
hog
liver
esteras
crude
human
lymphocyt
cem
cell
extract
also
use
hydrolysi
studi
secondli
molecular
model
studi
carri
investig
whether
arau
phosphoramid
lack
ester
aryl
motif
may
substrat
enzym
enzym
belong
phosphoramidas
famili
describ
process
compound
free
monophosph
result
discuss
chemistri
arau
synthes
two
step
scheme
first
reaction
format
anhydrouridin
thu
uridin
diphenyl
carbon
suspend
dmf
slurri
heat
point
potassium
carbon
k
co
ad
reaction
mixtur
heat
h
reaction
mixtur
allow
cool
room
temperatur
filter
white
solid
obtain
wash
methanol
afford
desir
compound
yield
second
reaction
open
anhydro
bond
gener
bhydroxyl
achiev
suspend
compound
water
n
hcl
ad
reaction
mixtur
heat
h
upon
neutral
aqueou
sodium
hydroxid
solvent
remov
residu
obtain
purifi
column
chromatographi
give
desir
compound
yield
arau
phosphoramid
synthesis
accord
previous
report
synthet
rout
develop
mcguigan
et
al
aryl
phosphorochlorid
prepar
reaction
phenyl
dichlorophosph
appropri
amino
acid
ester
hydrochlorid
tosyl
salt
obtain
phosphorochlorid
allow
react
arau
thf
pyridin
nmi
give
target
phosphoramid
moder
yield
p
nmr
investig
phosphoramid
display
two
close
space
signal
correspond
two
diastereoisom
result
mix
phosphat
stereochemistri
seri
arau
phosphoramid
bear
differ
ester
amino
acid
aryl
moieti
prepar
tabl
arau
prodrug
evalu
potenti
inhibitori
action
wide
varieti
dna
rna
virus
cell
cultur
unfortun
none
show
signific
antivir
activ
obtain
arau
phosphoramid
well
parent
nucleosid
arau
test
activ
select
myeloid
leukaemia
cell
line
cem
tabl
arau
show
low
lm
activ
versu
cell
line
test
best
cytostat
activ
shown
cell
line
ic
lm
phosphoramid
deriv
also
exhibit
rather
poor
activ
six
tumor
cell
line
test
notabl
arau
phosphoramid
clearli
cytostat
cell
compar
cell
line
evalu
reason
behind
activ
profil
remain
unclear
arau
phosphoramid
deriv
also
screen
activ
solid
tumour
cell
line
lovo
data
shown
tabl
failur
arau
phosphoramid
achiev
signific
antivir
anticanc
activ
may
result
three
factor
firstli
arau
phosphoramid
metabol
activ
monophosph
deriv
secondli
arau
monophosph
releas
insid
cell
phosphoryl
triphosph
counterpart
thirdli
arau
triphosph
might
inhibitori
antiviralcytostat
target
enzym
ie
dna
rna
polymeras
propos
metabol
aryl
phosphoramid
proce
four
step
eventu
releas
nucleosid
analogu
monophosph
shown
scheme
first
metabol
step
mediat
esteras
carboxypeptidas
enzym
cleav
ester
motif
aryl
phosphoramid
molecul
step
essenti
eventu
releas
nucleosid
analogu
monophosph
failur
stage
would
lead
releas
monophosph
probe
whether
ester
motif
arau
phosphoramid
cleav
carboxypeptidas
also
known
cathepsin
report
catalyz
hydrolysi
use
studi
phenyllalanin
benzyl
ester
arau
phosphoramid
chosen
test
experi
carri
h
room
temperatur
progress
reaction
follow
p
nmr
fig
shown
figur
phenyllalanin
benzyl
ester
phosphoramid
arau
appear
two
p
nmr
peak
correspond
two
diastereoisom
oblong
highlight
upon
addit
cathepsin
compound
quickli
hydrolyz
intermedi
min
lack
ester
motif
triangl
highlight
howev
intermedi
persist
turn
quickli
metabol
intermedi
ii
via
loss
aryl
motif
circl
highlight
intermedi
ii
consist
present
throughout
h
assay
suggest
within
h
cathepsin
abl
hydrolys
ester
aryl
moieti
phenyllalanin
benzyl
ester
phosphoramid
arau
pn
bond
peak
correspond
monophosph
detect
cleavag
pn
bond
aryl
phosphoramid
thought
proceed
via
involv
phosphoramidas
type
enzym
identifi
possibl
enzym
cleav
bond
thu
studi
use
dock
intermedi
ii
probe
possibl
hydrolysi
pn
bond
releas
arau
monophosph
silico
upon
dock
see
section
analysi
differ
predict
pose
show
intermedi
ii
conform
would
allow
interact
phosphat
moieti
key
residu
catalyt
site
although
sugar
hydroxyl
group
correctli
interact
aspart
acid
residu
pyrimidin
base
fit
hydrophob
pocket
fig
conform
retain
hydrogen
bond
interact
sugar
moieti
aspart
residu
show
sugar
ring
distort
consequ
base
push
outsid
hydrophob
pocket
comparison
amp
thin
red
line
fig
therebi
hydrolysi
pn
bond
may
effici
purin
ribo
nucleosid
analogu
tabl
cytostat
evalu
arau
phosphoramid
solid
tumour
cell
line
ic
lm
postul
mechan
action
aryl
triester
phosphoramid
find
agreement
hydrolysi
studi
perform
use
crude
human
cem
lymphocyt
extract
fig
hog
liver
esteras
data
shown
inde
diastereom
prodrug
could
separ
hplc
analysi
compound
expos
crude
cem
cell
extract
min
lalaninyl
glycinyl
arau
phosphoramid
prodrug
convert
correspond
intermedi
phosphoramid
deriv
releas
ester
aryl
moieti
except
compound
dalaninyl
deriv
remain
unalt
incub
period
fig
also
speed
convers
prodrug
compound
correspond
phosphoramid
intermedi
differ
depend
natur
esteraryl
part
prodrug
particular
compound
effici
convert
follow
glycinyl
prodrug
least
effici
convert
fig
use
purifi
hog
liver
esteras
ascertain
metabolit
appear
cem
cell
extract
inde
expect
lalaninyl
glycinyl
intermedi
prodrug
data
shown
interestingli
wherea
cem
cell
extract
hydrolyz
ester
moieti
prodrug
hog
liver
esteras
although
much
lower
effici
prodrug
applic
phosphoramid
technolog
wide
divers
riboand
deoxyribonucleosid
analogu
mostli
led
improv
biolog
activ
case
applic
arabinonucleosid
improv
biolog
activ
type
nucleosid
analogu
seem
affect
cleavag
pn
bond
thu
outcom
use
pronucleotid
technolog
seri
arau
phosphoramid
synthes
investig
antivir
activ
cytotox
versu
six
leukaemia
cell
line
four
solid
tumour
cell
line
unfortun
none
phosphoramid
parent
nucleosid
arau
show
signific
activ
metabol
assay
use
carboxypeptidas
hog
liver
esteras
show
abil
enzym
metabol
ester
motif
arau
phosphoramid
subsequ
spontan
phenyl
loss
molecular
model
studi
suggest
arau
lalanin
aminoacyl
phosphat
may
good
substrat
crude
cem
cell
extract
format
phosphoramid
intermedi
seen
lalaninyl
glycinyl
prodrug
dalaninyl
prodrug
format
arau
monophosph
observ
thu
hydrolysi
studi
dock
suggest
effici
pn
bond
cleavag
releas
arau
monophosph
might
contributor
poor
cytotox
activ
arau
protid
taken
togeth
result
suggest
poor
cytostat
activ
arau
phosphoramid
could
result
ineffici
pn
cleavag
though
poor
phosphoryl
diand
triphosph
could
also
reason
poor
biolog
activ
studi
suggest
phosphoramid
protid
may
limit
efficaci
arabino
nucleosid
although
exact
scope
conclus
need
confirm
experi
involv
watersensit
compound
carri
dri
condit
solvent
use
dri
use
purchas
aldrich
glasswar
ovendri
sever
hour
allow
cool
steam
dri
nitrogen
thinlay
chromatographi
tlc
perform
use
precoat
aluminiumback
silica
gel
plate
mm
thick
suppli
e
merck
ag
darmstad
germani
visualis
plate
achiev
use
ultraviolet
uv
lamp
glass
column
slurrypack
appropri
eluant
pressur
silica
gel
lm
phase
separ
ltd
deesid
clwyd
uk
sampl
appli
concentr
solut
eluant
preabsorb
silica
gel
fraction
contain
product
identifi
tlc
pool
solvent
remov
vacuo
h
c
p
nmr
spectra
record
bruker
avanc
mhz
spectromet
autocalibr
deuter
solvent
refer
peak
follow
abbrevi
use
assign
nmr
signal
singlet
doublet
triplet
q
quartet
multiplet
hplc
analyt
investig
conduct
varian
prostar
instrument
lc
work
station
varian
prostar
lc
detector
use
polari
lm
column
eluant
perform
use
mobil
phase
consist
wateracetonitril
gradient
electrospray
mass
spectra
obtain
use
water
lct
time
flight
tof
mass
spectromet
coupl
water
hplc
pump
data
collect
continuum
mode
mass
rang
amu
process
use
masslynx
softwar
hydroxymethyl
one
uridin
g
mmol
diphenyl
carbon
g
mmol
suspend
dmf
ml
slurri
heat
sodium
bicarbon
mg
ad
reaction
mixtur
heat
h
complet
reaction
cool
room
temperatur
filter
wash
methanol
ml
follow
dri
vacuum
h
titl
compound
obtain
white
solid
yield
g
compound
g
mmol
ml
n
hcl
heat
h
reaction
mixtur
cool
neutral
ph
sodium
hydroxid
solvent
remov
crude
purifi
column
chromatographi
employ
methanol
dcm
eluant
pool
evapor
appropri
fraction
gave
titl
compound
g
yield
white
solid
arau
equiv
dissolv
ml
thfpyridin
argon
nmi
equiv
ad
reaction
flask
follow
addit
appropri
phosphorochlorid
equiv
mixtur
stir
room
temperatur
h
upon
remov
solvent
crude
purifi
column
chromatographi
ch
cl
ch
oh
prepar
hplc
give
desir
product
white
solid
arau
phosphoramid
evalu
six
myeloid
cell
type
cem
vitro
inhibitori
concentr
ic
cell
growth
reduc
cell
count
assay
cem
use
coulter
counter
longer
viabl
calcul
use
mt
assay
determin
cell
treat
arau
protid
concentr
lm
lm
serial
dilut
incub
h
co
final
volum
twenti
microlit
mt
reagent
promega
uk
ltd
southampton
hant
ad
tumor
cell
cultur
reaction
incub
h
co
absorb
reaction
time
read
spectrophotometri
nm
percentag
viabl
cell
calcul
rel
untreat
control
cell
assay
antitumour
evalu
lovo
cell
line
perform
use
mtt
assay
protid
prepar
mm
stock
solut
dissolv
dmso
store
cell
seed
microtitr
plate
densiti
cell
per
well
allow
h
adher
decim
protid
dilut
prepar
medium
immedi
prior
assay
final
concentr
lm
follow
h
protid
exposur
co
mtt
reagent
sigma
aldrich
ad
well
final
concentr
mgml
incub
h
allow
reduct
mtt
viabl
cell
insolubl
formazan
product
mtt
remov
formazan
solubilis
addit
triton
pb
absorb
read
tecan
sunris
plate
reader
nm
measur
cell
viabil
thu
inhibit
rel
control
determin
ic
phosphoramid
prodrug
mg
dissolv
aceton
trizma
buffer
ph
ad
result
cloudi
solut
place
nmr
tube
p
nmr
experi
record
blank
experi
frozen
enzym
carboxypeptidas
ec
mg
left
reach
room
temperatur
least
min
solubilis
trizma
ad
solut
phosphoramid
nmr
tube
immedi
tube
place
nmr
machin
set
run
p
nmr
experi
scan
everi
min
h
data
process
analys
bruker
topspin
program
molecular
model
studi
perform
macpro
dual
ghz
xeon
run
ubuntu
use
molecular
oper
environ
moe
flexx
biosolveit
flexx
biosolveit
gmbh
der
ziegelei
sankt
augustin
germani
http
wwwbiosolveitdeflexx
hydrogen
atom
ad
crystal
structur
pdb
code
minimis
moe
gradient
kcal
mol
reach
use
forcefield
partial
charg
automat
calcul
dock
experi
carri
use
moe
gui
flexx
implement
moe
arau
analogu
built
moe
minimis
dock
compound
evalu
follow
virus
herp
simplex
viru
type
strain
ko
thymidin
kinasedefici
tk
ko
strain
resist
acv
acv
r
herp
simplex
viru
type
strain
g
vaccinia
viru
lederl
strain
respiratori
syncyti
viru
rsv
strain
long
vesicular
stomat
viru
vsv
coxsacki
parainfluenza
sindbi
punta
toro
influenza
viru
type
type
b
felin
corona
viru
antivir
antihiv
assay
base
inhibit
virusinduc
cytopath
human
embryon
lung
hel
fibroblast
african
green
monkey
cell
vero
human
epitheli
cervix
carcinoma
cell
hela
crandel
felin
kidney
cell
cfkc
madindarbi
canin
kidney
cell
mdck
briefli
confluent
cell
cultur
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
h
adsorpt
period
residu
viru
remov
cell
cultur
incub
presenc
vari
concentr
test
compound
viral
cytopath
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopath
cytotox
test
compound
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
cell
morpholog
examin
inhibit
hivinduc
cytopath
cem
cell
human
cem
cell
cultur
cell
ml
infect
ccid
iii
b
rod
per
ml
seed
llwell
microtit
plate
contain
appropri
dilut
test
compound
day
incub
syncytia
format
examin
microscop
cem
cell
cultur
ec
valu
determin
describ
cytostat
compound
concentr
calcul
cc
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
cc
valu
estim
graphic
plot
number
cell
percentag
control
function
concentr
test
compound
prodrug
convers
studi
presenc
crude
cell
extract
cem
cell
extract
prepar
exponenti
grow
cell
suspend
ml
pb
upon
sonic
destroy
integr
cell
subsequ
centrifug
remov
cell
debri
six
hundr
microlit
incub
medium
contain
cell
extract
pb
test
compound
lm
dmso
prepar
kept
min
time
point
withdrawn
incub
medium
ad
icecold
methanol
final
concentr
min
reaction
mixtur
centrifug
rpm
min
supernat
analyz
revers
phase
hplc
retent
time
enantiom
min
tr
min
tr
min
tr
min
tr
min
separ
parent
compound
convers
product
perform
revers
phase
rpselect
b
column
merck
darmstadt
germani
use
follow
gradient
min
acetonitril
buffer
min
linear
gradient
buffer
buffer
b
mm
nah
po
mm
heptan
sulfon
acid
min
linear
gradient
buffer
buffer
b
min
linear
gradient
buffer
buffer
b
min
linear
gradient
buffer
buffer
b
min
isocrat
flow
min
linear
gradient
buffer
buffer
b
min
equilibr
buffer
buffer
b
convers
prodrug
hog
liver
esteras
boehring
mannheim
germani
mm
mgcl
mm
ph
analys
anion
exchang
hplc
retent
time
land
dalaninyl
phosphoramid
intermedi
min
glycinyl
phosphoramid
intermedi
min
follow
anion
exchang
column
partispheresax
whatman
maidston
uk
gradient
use
min
buffer
mm
nh
h
po
ph
min
linear
gradient
buffer
b
mm
nh
h
po
ph
min
buffer
b
min
linear
gradient
buffer
min
buffer
equilibr
